
On November 20, 2026, clinical-stage oncology company Erasca reported updated Phase 1 trial data for its oral pan-RAS molecular glue ERAS-0015, demonstrating a 44% confirmed objective response rate in pretreated pancreatic cancer patients in its AURORAS-1 study release, marking a pivotal milestone for translational oncology centres and academic clinical trial sponsors evaluating next-generation RAS pathway inhibitors across difficult-to-treat solid tumours.
Clinical Trial Findings and Response Rates Across KRAS Mutations
The Phase 1/1b AURORAS-1 study, catalogued under ClinicalTrials.gov record NCT06983743, evaluated the safety, pharmacokinetics, and preliminary antitumour activity of ERAS-0015 in patients with advanced RAS-mutant solid tumours. The pancreatic ductal adenocarcinoma (PDAC) expansion cohort enrolled 122 patients whose disease had progressed following two or more prior systemic therapies, with 84% having received three or more prior lines. In this heavily pretreated population where standard chemotherapy options rarely achieve double-digit response rates, ERAS-0015 demonstrated meaningful single-agent clinical activity.
At the recommended expansion dose of 32 mg orally once daily (QD), ERAS-0015 achieved a confirmed overall response rate (ORR) of 44% across evaluable patients with KRAS G12X-mutant PDAC. Efficacy was observed across multiple distinct oncogenic variants. Among patients harbouring the KRAS G12D mutation—the most common oncogenic driver in pancreatic cancer—the confirmed ORR was 63%. In patients with the KRAS G12V alteration, the confirmed ORR reached 80%, while the KRAS G12R subset demonstrated a 44% confirmed response rate.
Erasca also reported data from an expansion cohort of patients with KRAS G12X-mutant non-small cell lung cancer (NSCLC) refractory to platinum chemotherapy and immunotherapy, achieving a 60% confirmed ORR at the 32 mg once-daily dose. ERAS-0015 maintained a manageable safety profile across evaluated dose levels (16 mg to 32 mg daily), with adverse events predominantly low-grade (Grade 1–2). Treatment-related discontinuation rates remained below 5%, with low frequencies of dose reductions or interruptions.
Study Design, Dosing Cohorts, and Bristol Myers Squibb Partnership Terms
AURORAS-1 operates as an open-label, multicentre trial combining Bayesian dose escalation with indication-specific expansion cohorts. Pharmacodynamic assessments demonstrated deep suppression of downstream phosphorylated ERK (pERK) signaling at steady-state plasma exposures, confirming target engagement across mutant RAS isoforms.
Concurrent with the clinical update, Erasca announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb, reported by BioPharma Boardroom. The partners will evaluate ERAS-0015 in combination with BMS’s investigational PRMT5 inhibitor navlimetostat (BMS-986504) in a Phase 1/2 trial for MTAP-deleted pancreatic cancer.
Under the contractual terms, Bristol Myers Squibb will sponsor the clinical trial, while Erasca supplies ERAS-0015. Both companies retain independent development and commercial rights to their individual assets under mutually non-exclusive terms. The combination targets a synthetic lethality vulnerability, as MTAP-deleted pancreatic tumours frequently harbour co-occurring activating KRAS mutations that sensitise cells to dual pathway inhibition.
| Trial Cohort / Indication | Dose & Schedule | Line of Therapy | Mutation Subgroup | Confirmed ORR (%) |
|---|---|---|---|---|
| AURORAS-1 PDAC Expansion | 32 mg Oral QD | 2L+ (84% 3L+) | KRAS G12X Overall | 44% |
| AURORAS-1 PDAC Expansion | 32 mg Oral QD | 2L+ (84% 3L+) | KRAS G12D Mutation | 63% |
| AURORAS-1 PDAC Expansion | 32 mg Oral QD | 2L+ (84% 3L+) | KRAS G12V Mutation | 80% |
| AURORAS-1 PDAC Expansion | 32 mg Oral QD | 2L+ (84% 3L+) | KRAS G12R Mutation | 44% |
| AURORAS-1 NSCLC Expansion | 32 mg Oral QD | 2L / 3L Post-IO/Platinum | KRAS G12X Overall | 60% |
| BMS Combination (Planned) | ERAS-0015 + Navlimetostat | Phase 1/2 Escalation | MTAP-Deleted PDAC | Trial Initiation 2027 |
Evolution of RAS Therapeutics and Molecular Glue Mechanics
For decades, the RAS family of small GTPases was considered undruggable due to picomolar nucleotide affinity and an absence of conventional hydrophobic binding pockets. First-generation targeted inhibitors achieved regulatory approvals only for inactive, GDP-bound KRAS G12C, leaving the vast majority of pancreatic cancers—dominated by G12D and G12V—without targeted options.
ERAS-0015 functions as an oral pan-RAS molecular glue that engages endogenous cyclophilin A to assemble a high-affinity interface against both active (GTP-bound) and inactive (GDP-bound) conformations of KRAS, NRAS, and HRAS. This steric hindrance obstructs effector recruitment and halts downstream oncogenic MAPK signaling across multiple codon alterations.
In August 2026, the FDA granted FDA Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma, as noted by oncology outlet CancerNetwork. Methodological standards for evaluating solid tumour responses in early precision oncology trials are detailed in CASRAI’s analyses of oncology clinical trial endpoints and the structure of clinical trial phases.
Oncology Sector Reaction and Competitive Differentiation
The Phase 1 release prompted close comparison with competing RAS programs, particularly Revolution Medicines’ pan-RAS candidate Rasonque (daraxonrasib), as covered by BioPharma Dive. Rasonque previously reported overall response rates of 32% in similar pretreated pancreatic cancer cohorts, including 24% in G12D and 50% in G12V subsets.
RBC Capital Markets analyst Leonid Timashev noted in an investor report that the data suggest ERAS-0015 “could be a formidable competitor in the future, and potentially accelerate the fragmentation of the RAS landscape,” highlighting that the molecule “continues to demonstrate a better profile on both efficacy and safety in what was a challenging population—suggesting what may be real differentiation.”
Leerink Research analyst Asthika Goonewardene observed that ERAS-0015’s lower incidence of treatment-related toxicities could offer “opportunities to carve out niches that Rasonque may not be able to access” owing to overlapping toxicities when paired with chemotherapy or targeted backbones.
TD Cowen analyst Tyler Van Buren offered a cautionary perspective, noting that cross-trial comparisons carry inherent limitations and that early Phase 1 response rates must be confirmed in larger randomized studies against established commercial and clinical benchmarks.
Commenting on the clinical strategy, Dr. Jonathan E. Lim, M.D., Erasca’s Chairman and CEO, stated: “The early clinical activity demonstrated by ERAS-0015 has been encouraging, and we are excited to collaborate with BMS to further explore its potential in combination with navlimetostat. By bringing together complementary mechanisms with strong scientific rationale, this combination expands the potential of ERAS-0015 as a backbone of choice across RASm cancers.”
Implications for University Cancer Centres and Clinical Trial Infrastructure
For comprehensive cancer centres and academic trial offices operating within the clinical research landscape, advancing pan-RAS molecular glues and multi-sponsor combinations introduces distinct operational and governance requirements. Research teams must manage complex protocols coordinating supply chains and toxicity tracking across distinct commercial partners.
Institutional Review Boards (IRBs) and clinical trial offices must structure clinical trial agreements (CTAs) that clearly establish indemnification and safety reporting responsibilities when one pharmaceutical firm sponsors a trial utilizing an investigational drug supplied by a collaborating biotechnology developer. Data-sharing and biospecimen intellectual property agreements must be rigorously partitioned.
Additionally, clinical pathology laboratories must expand molecular profiling. Identifying eligible patients requires comprehensive next-generation sequencing (NGS) panels that accurately resolve specific KRAS codon 12 variants, alongside validated immunohistochemistry (IHC) or copy-number assays for MTAP gene deletion to support enrollment into synthetic lethality combination arms.
Next Regulatory and Clinical Milestones for 2027
Erasca announced that it is accelerating the initiation of a global, randomized Phase 3 trial in first-line pancreatic ductal adenocarcinoma to the first half of 2027, evaluating ERAS-0015 in combination with standard gemcitabine and nab-paclitaxel regimens.
The company also plans to launch Phase 3 registration-enabling trials in second-line non-small cell lung cancer in 2027, following regulatory consultations on comparative trial designs and primary endpoints.
The Bristol Myers Squibb combination study in MTAP-deleted PDAC is scheduled to open site activation and patient enrollment in 2027. Furthermore, Erasca plans to initiate combination dose escalation pairing ERAS-0015 with its internal pan-KRAS inhibitor, ERAS-4001, to explore dual-inhibitor approaches to suppress resistance mechanisms.
Sources
- Erasca: Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015, checked 2026-11-21
- ClinicalTrials.gov: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors (AURORAS-1), checked 2026-11-21
- BioPharma Dive: Erasca data add to pressure facing Revolution’s breakthrough cancer drug, checked 2026-11-21
- BioPharma Boardroom: Erasca and Bristol Myers Squibb Partner to Test ERAS-0015 Combination in Pancreatic Cancer, checked 2026-11-21
- CancerNetwork: FDA Grants Fast Track Designation to ERAS-0015 for Pancreatic Adenocarcinoma, checked 2026-11-21







